CPT2 and prostate carcinoma: Inhibition of CPT1 with either genetic or pharmacological manipulation has been shown to reduce total ATP levels and the rate of ATP production in PC3 prostate cancer cells [62], Burkitt's lymphoma cells [191], and human glioblastoma cells [192] to impair proliferation.